本人李梦涓，已充分了解并同意由提名人北京热景生物技术股份 有限公司董事会提名为北京热景生物技术股份有限公司第四届董事 会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任北京热景生物技术股份有限公司独立董 事独立性的关系，具体声明并承诺如下： 北京热景生物技术股份有限公司 独立董事候选人声明与承诺 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有五年以上法律、经济会计、财 务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》等关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》和上海证券交 易所自律监管规则有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 ...

Core Viewpoint - The Chinese biotechnology sector is experiencing significant revaluation, driven by a surge in licensing deals between Chinese biotech companies and global pharmaceutical giants, particularly in the PD-1/VEGF bispecific antibody field [1][2]. Group 1: Biotechnology Sector - The Chinese biotechnology sector has risen by 72% year-to-date, significantly outperforming the MXCN index, which has increased by 17% [1]. - Key licensing deals include collaborations between companies such as CanSino Biologics and Summit, 3S Bio and Pfizer, and Boteng Co. with BioNTech/BMS [2]. - Goldman Sachs anticipates that the momentum in licensing deals will continue, with more transactions expected to be announced [3]. Group 2: CDMO/CRO Opportunities - The CDMO/CRO sector has seen a 25% increase year-to-date, with companies like Tigermed gaining attention due to a 20% year-on-year growth in new orders in Q1 [3]. - Discussions around Samsung Biologics' potential spin-off of Bioepis are highlighted as a strategic move to optimize profitability and maintain competitiveness in the core CDMO business [3]. Group 3: Medical Devices Sector - The medical device sector has declined by 4% year-to-date, while the medical services sector has dropped by 7%, raising questions about their potential for revaluation following the biotech sector [4]. - Equipment procurement has shown signs of recovery, with a 91% year-on-year increase in May, despite a 13% month-on-month decline [4]. - Companies like United Imaging and Mindray are expected to see market growth in China, with projections for total revenue and profit growth of 24% and 42% respectively by 2025 [4]. Group 4: Global Pharmaceutical Trends - Global pharmaceutical and biotech companies are recognizing the value of Chinese assets, with business development transactions remaining a priority [5]. - Recent activities in the PD-1/L1xVEGF bispecific antibody space illustrate this trend, with companies leveraging data from China to support development plans [5].

Core Points - The company announced a cash dividend of 0.56 RMB per share (including tax) for the 2024 fiscal year [2][4] - The dividend distribution plan was approved at the annual shareholders' meeting on May 22, 2025 [2][4] - The total number of shares eligible for profit distribution is 134,345,456 shares, resulting in a total cash dividend payout of approximately 75.23 million RMB (including tax) [4] Dividend Distribution Details - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the equity registration date [3] - The company will not issue new shares or increase capital reserves during this dividend distribution [4][7] - The reference price for ex-dividend trading will be adjusted based on the cash dividend and the number of shares [7] Tax Implications - Individual shareholders holding unrestricted shares for over one year will be exempt from personal income tax on the dividend [11] - For shares held for less than one year, the company will not withhold tax at the time of distribution, but tax will be calculated and deducted upon the sale of the shares [11][12] - The actual cash dividend received by shareholders may vary based on their holding period and applicable tax rates [12][13] Share Buyback Program - The company adjusted the maximum buyback price from 50.00 RMB per share to 49.45 RMB per share, effective June 24, 2025 [16][18] - The buyback program aims to repurchase shares for employee stock ownership plans or equity incentives, with a total buyback amount between 50 million RMB and 100 million RMB [17][21] - The adjusted buyback price will allow for the repurchase of approximately 1,011,122 to 2,022,244 shares, representing 0.7410% to 1.4820% of the total share capital [21]

证券代码：688253 证券简称：英诺特 公告编号：2025-027 北京英诺特生物技术股份有限公司 关于 2024 年年度权益分派实施后调整回购股份价格 上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 调整前回购股份价格上限：不超过人民币 50.00 元/股（含）。 ? 调整后回购股份价格上限：不超过人民币 49.45 元/股（含）。 ? 股份回购价格上限调整起始日期：2025 年 6 月 24 日。 一、回购股份的基本情况 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上 海证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机拟用 于员工持股计划或股权激励。公司本次回购价格不超过人民币 50.00 元/股（含）， 回购股份金额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含）， 回购股份的实施期限自董事会审议通过本次回购方案之日起 12 个月内。 具 体 内 容 详 见 公 司 于 2024 年 8 月 3 日 在 上 海 证 ...

华泰联合证券有限责任公司 关于北京英诺特生物技术股份有限公司 差异化分红事项的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作为 北京英诺特生物技术股份有限公司（以下简称"英诺特"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、 《上 海证券交易所科创板股票上市规则》及《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等相关规定，对英诺特差异化分红送转特殊除权除 息（以下简称"本次差异化分红"）的事项进行了审慎核查，具体情况如下： 一、本次差异化分红的原因 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，在未来适宜时机拟用于 员工持股计划或股权激励。公司拟用于本次回购的资金总额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回购价格为不超过人民币 50 元/股 （含），回购股份的实施期限自董事会审议通过本次回购方案之日起 12 个月内。 具体内容详见公司分别于 2024 年 8 月 3 日、2024 年 8 月 8 ...

Core Viewpoint - The company, Beijing Innotech Biotechnology Co., Ltd., has announced a differentiated cash dividend distribution plan, approved at the 2024 annual shareholders' meeting, with a cash dividend of 0.56 yuan per share (including tax) [1][2]. Dividend Distribution Plan - The total share capital of the company is 136,458,196 shares, with 2,112,740 shares held in the company's repurchase account, resulting in 134,345,456 shares eligible for profit distribution [2]. - The total cash dividend to be distributed amounts to 75,233,455.36 yuan (including tax) [2]. - The cash dividend distribution will be based on the total share capital minus the shares in the repurchase account, with no stock dividends or capital reserve transfers [1][2]. Relevant Dates - The key dates for the dividend distribution are the record date, ex-dividend date, and cash dividend payment date [3]. Implementation of Distribution - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered by the record date [3]. - Shares held in the company's repurchase account will not participate in this dividend distribution [3]. Taxation on Dividends - For individual shareholders holding unrestricted shares for over one year, the cash dividend is exempt from personal income tax, resulting in a net distribution of 0.56 yuan per share [4][5]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the sale of the shares [4][5]. - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, leading to a net cash dividend of 0.504 yuan per share [6]. - Hong Kong investors will also have a 10% tax withheld, resulting in a net cash dividend of 0.504 yuan per share [6]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's securities department at the provided phone number [7].

生物技术公司Sarepta盘前下跌30%，公司报告出现第二例基因治疗相关死亡。 ...

中青报·中青网记者 王海涵 王磊 眼下，正逢夏收时节，安徽农业大学农学院2025届应届毕业生杨森林已经奔波在农忙的道路上。在合肥 市肥东县一处试验田，眼前一片金黄的麦田收割完毕，杨森林忙碌起来，别人眼中普通的麦粒对他来说 却是一个个"宝贝"，"这些都是不同的种质资源，我们从中分析鉴定出优异基因，进行遗传改良，就可 能成为一个优质品种的原材料。" 今年一开年，杨森林就和安徽荃银高科种业公司签约就业协议。一边忙着毕业事宜，一边忙着农业业务 上的事。对杨森林来说，见证和助力麦田丰收，就是最好的毕业论文和求职简历。几个月下来，他褪去 了大学生的青涩，俨然成了公司的"老员工"。 安徽农业 大学农学院学生在麦田里实践。安徽农业大学供图 和杨森林一样，当时和这家公司签约的还有农学院十几名毕业生。之所以一次性签约多名毕业生，用公 司负责人的话来说："基础扎实，动手能力强，踏实肯干，一个词：放心。" 近三年来，安徽农业大学共有本硕毕业生26103人，其中68.6%的毕业生扎根基层一线就业，74.37%毕 业生留在安徽就业，475名毕业生扎根西部，202名毕业生应征入伍。 从学生到员工"无缝对接" 这种"在校如在企、入企即上岗" ...

Core Viewpoint - The article highlights the growing recognition and success of Chinese biotech companies in the global market, particularly through the development of proprietary technologies and platforms, exemplified by the recent patent authorization of the RenMab® platform by BaiOsaite [1][2][4]. Group 1: Technological Advancements - BaiOsaite's RenMab® platform received a patent from the Japan Patent Office, marking a significant achievement in China's biotech innovation [1]. - The platform utilizes a proprietary technology called SUPCE® to humanize mouse antibody variable region genes, addressing key challenges in antibody drug development [2]. - The platform has gained international attention, with collaborations established with major companies like Merck and Johnson & Johnson, resulting in a large-scale antibody discovery project targeting over 1,000 potential drug targets [4]. Group 2: Market Trends and Collaborations - In 2024, over 94 license-out transactions for Chinese innovative drugs were recorded, with 41 occurring in the first quarter of 2025, totaling over $36.9 billion in transaction value [6]. - Notable deals include IBI3009's global licensing agreement with Roche, which includes an upfront payment of $80 million and potential milestone payments up to $1 billion [5]. - The focus on PD-1/VEGF bispecific antibodies has attracted significant international interest, with major agreements involving Pfizer and Merck [6]. Group 3: Intellectual Property and Global Strategy - Chinese biotech companies are shifting their focus from merely exporting products to also exporting platforms and intellectual property, recognizing the higher commercial potential in original technologies [7][8]. - Companies like BaiOsaite and Innovent Biologics are demonstrating systematic capabilities in intellectual property layout, enhancing their negotiating power in international collaborations [8]. - The future of competition in biomedicine will hinge on establishing ecosystems and standards, with a focus on building technological barriers and deep collaborations with upstream and downstream partners [9][10].

Core Viewpoint - BioNTech has agreed to acquire CureVac for approximately $1.25 billion in an all-stock deal, enhancing its oncology business and ending a long-standing competitive relationship [1][2]. Group 1: Acquisition Details - The acquisition price offers CureVac shareholders about 5.46 shares of BioNTech for each CureVac share, representing a 34% premium over CureVac's closing price prior to the announcement [1]. - Following the transaction, CureVac shareholders will hold between 4% to 6% of BioNTech's shares [1]. - CureVac's stock rose by 31.20% in pre-market trading after the announcement [1]. Group 2: Strategic Shift - CureVac has shifted its focus from infectious disease research to cancer immunotherapy, having sold its vaccine business to GlaxoSmithKline [2]. - BioNTech's CEO, Ugur Sahin, emphasized that oncology is a key area for BioNTech, and the acquisition will integrate complementary resources to enhance its cancer treatment capabilities [2]. Group 3: Government Involvement - The German government, which holds a 13.3% stake in CureVac, will receive approximately $163 million in BioNTech stock as part of the deal [2]. - The German government has expressed a positive attitude towards the transaction [2]. Group 4: Broader Business Strategy - This acquisition is part of BioNTech's strategy to reinvest substantial funds from its COVID-19 vaccine success into expanding its cancer treatment business [2]. - Earlier this month, BioNTech licensed a new generation cancer drug to Bristol-Myers Squibb for up to $11.1 billion [2].